On 20 May 2024, Teva and Alvotech announced that their interchangeable high concentration citrate-free adalimumab biosimilar Simlandi® (adalimumab-ryvk, AVT02) is now available in the US. Simlandi® is indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
Simlandi® was FDA approved in February 2024 as the first interchangeable, high-concentration, citrate-free biosimilar to Humira. Alvotech reports that nearly 88% of adalimumab prescriptions in the US are for the high-concentration formulation.
In July 2023, Teva and Alvotech announced a $40 million expansion to their US biosimilar partnership. The agreement involved milestone payments and shared profits from the commercialisation of the biosimilars.